BLAINJECTIONINJECTABLE1 Generic Approved
Approved
Apr 2016
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
7/8 — Comprehensive
INFLECTRA (infliximab-dyyb) by Celltrion is tumor necrosis factor receptor blocking activity [moa]. Approved for tumor necrosis factor blocker [epc]. First approved in 2016.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INFLECTRA (infliximab-dyyb) is a monoclonal antibody TNF receptor blocker manufactured by Celltrion and approved by the FDA on April 5, 2016. It works by blocking tumor necrosis factor, a key inflammatory cytokine implicated in autoimmune and inflammatory diseases. INFLECTRA is indicated for TNF-mediated inflammatory conditions and is positioned as a biosimilar alternative in a crowded TNF inhibitor market dominated by original innovator products and competing biosimilars.
$0.0BPart D
Mechanism of Action
Tumor Necrosis Factor Receptor Blocking Activity
Pharmacologic Class:
Tumor Necrosis Factor Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (4)
Zymfentra (Infliximab-dyyb) REal World Cohort STudy
Started Nov 2025
200 enrolled
Ulcerative Colitis (UC)Crohn's Disease (CD)Indeterminate Colitis+1 more
This is a Retrospective Observational Study Looking at the Characteristics and Outcomes of Participants Taking Inflectra Using the CorEvitas Rheumatoid Arthritis Registry
Started Nov 2022
255 enrolled
Arthritis, Rheumatoid
Observational, Real World Study Of Inflectra In Patients With Inflammatory Bowel Disease
Started Feb 2018
118 enrolled
Inflammatory Bowel Disease (IBD)Crohn's Disease (CD)Ulcerative Colitis (UC)
National Observational Study On The Use Of Inflectra™ An Infliximab Biosimilar In Real Life
Started Oct 2016
1,431 enrolled
Crohn DiseaseUlcerative ColitisRheumatoid Arthritis+2 more
Worked on INFLECTRA at Celltrion? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.